James R. Hagman, PhD Ask a Question Refer Patient James R. Hagman, PhD, is a researcher at National Jewish Health. Dr. Hagman is in the Department of Biomedical Research. Professor Department of Biomedical Research 5280 Top Doctors 2019 Previously a 5280 Top Doctor America’s Top Doctors 2015 — Castle Connolly, Medical, Ltd. Recognized in America’s Top Doctors — Castle Connolly, Inc. Best Doctors in America® 2018-2019 — Best Doctors, Inc. Recognized in Best Doctors in America® — Best Doctors, Inc. America’s Top Doctors 2019 — Castle Connolly Medical, Ltd. Email Profile Print Profile × No Rating Available In order to provide the most accurate and useful information on our providers, we only post satisfaction data when a provider has received a minimum of 30 survey responses. We have not yet received the minimum number of surveys for this provider, or this provider is a researcher who only sees a limited number of patients in clinic. To learn more about this survey, visit our about the Press Ganey Survey page. Close Overview Contact Info & Locations Research Areas Antibodies B Cells Epigenetics Gene Expression Leukemia/Lymphoma Special Interests Research Interests Regulation of B cell transcription and development Lymphocyte differentiation proceeds through multiple stages characterized by the expression of distinct sets of genes. My laboratory’s goals include understanding how the nuclear proteins Early B cell Factor (EBF) and Pax5 (B cell-specific activator protein) regulate B lineage specification, commitment and the immune response to antigens. EBF has been identified as a crucial factor for lineage determination. EBF regulates many genes (such as mb-1) involved in assembly of the pre-B and mature B cell receptors for antigen (pre-BCR and BCR). We recently identified EBF as an early mediator of changes in mb-1 gene chromatin structure, including DNA demethylation and enhanced accessibility. Pax5 acts downstream of EBF as an important regulator of the early B cell-specific transcriptome, but is also important at later stages of B cell maturation. Notably, Pax5 is a key factor for establishing B cell lineage commitment. To better understand how these proteins function in B cells, my lab employs a combination of biochemical and genetic methods, including transgenic and gene targeted mice. Ultimately, we wish to understand how regulatory signals are integrated for activation and/or repression of genes that contribute to normal immunity, immune diseases, and cancer. Education Education 1989 University of Washington, Seattle, PhD, Microbiology 1986 University of Washington, Seattle, MS, Microbiology 1979 University of California, Berkeley, BA, Genetics Residency Howard Hughes Medical Institute, Postdoctoral University of California, San Francisco, Postdoctoral Awards & Recognition 2009-2013: Member, NIH CMI-B Study Section 2006-2011: Editorial Board, Journal of Biological Chemistry 2008-Present: Advisory Board, Faculty of 1000 Biology 2008: Ad hoc Member, NIH Special Emphasis Panel/Scientific Review Group ZRG1 IMM-J (02) 2007: Research Award, Rocky Mountain Chapter of the Arthritis Foundation 2007: Co-editor, Current Opinion in Immunology, Lymphocyte Development 2000-2001, 2006-2007: Scientific Advisory Board Member, Cancer League of Colorado 2005: Outstanding Scientific Achievement Award, National Jewish Health 1997-2005: Ad hoc Member, NIH Special Emphasis Panel ZRG IMB 01 1997-2001: Peer Review Committee on Development, Differentiation and Cancer, Regular Member, American Cancer Society 1997: Harmon Foundation Award for Arthritis Research 7/1990-6/1993: Fellow of the Leukemia Society of America Professional Memberships The Epigenetics Society American Society for Biochemistry and Molecular Biology Member, American Society of Microbiology Member, American Association of Immunologists Member, American Association for Cancer Research Publications Lukin, K, S Fields, L Guerrettaz, D Straign, V Rodriguez, S Zandi, R Månsson, JC Cambier, M Sigvardsson and J Hagman. 2011. A dose-dependent role for EBF1 in repressing non-B cell specific genes. Eur J Immunol, 41:1787-1793 (PMCID: PMC3127254). Musselman, CA, J Ramirez, JK Sims, RE Mansfield, SS Oliver, JM Denu, JP Mackay, PA Wade, J Hagman and TG Kutateladze. 2012. Bivalent recognition of nucleosomes by the tandem PHD fingers of CHD4 is required for CHD4-mediated repression. Proc Natl Acad Sci USA, 109:787-792 (PMCID: PMC3271909). Hagman, J, J Ramírez and K Lukin. 2012. B lymphocyte lineage specification, commitment and epigenetic control of transcription by Early B cell Factor 1. Curr Topics Micro Immunol, 356:17-38 (PMID: 21735360). Dege, C, and J Hagman. 2012. Activation of Aicda gene transcription by Pax5 in plasmacytoma cells. Immunol Res, [Epub ahead of print] (PMID: 22956488). Ramirez, J, C Dege, KG Kutateladze and J Hagman. 2012. MBD2 and multiple domains of CHD4 are required for transcriptional repression by Mi-2/NuRD complexes. Mol Cell Biol, [Epub ahead of print] (PMID: 23071088). Academic Affiliations University Page for Dr. Hagman Conflicts of Interest National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations. Ask a Question through Patient Portal Sign in to your My National Jewish Health patient portal account to communicate with your care team, manage appointments, and more. Create an Account Contact Information Office: 877.225.5654Fax: 303.398.1396 Locations National Jewish Health Main Campus 1400 Jackson St. Denver, CO 80206 Patient Ratings The Patient Rating score is an average of all responses to care provider related questions on our independent rating system, the Press Ganey Patient Satisfaction Survey. This survey is about the patient care experience and does not address crucial characteristics like medical decision-making, prescribing the best therapy, and patient outcomes. Responses are measured on a scale of 1 to 5, with 5 being the best score. Learn more about our patient satisfaction survey. Comments Comments are collected in our Press Ganey Patient Satisfaction Surveys. Patients are de-identified to protect confidentiality and patient privacy. Learn more about our patient satisfaction survey.